This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

11 Biotech Stocks Loved or Hated by Hedge Funds

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Oncothyreon (ONTY)

Another cancer immunotherapy, or "cancer vaccine" stock hoping to replicate the success of Dendreon while sidestepping Provenge's problems. Oncothyreon and its partner Merck KGaA are gearing up to perform an interim analysis on a phase III study of their Stimuvax immunotherapy in non-small cell lung cancer patients. Trading volume and volatility in Oncothyreon have increased dramatically in recent months as investors focus hard on this interim analysis, which is expected in the first quarter of next year.

Year to date performance: + 107%

Performance since June 30: -26%

Three hedge funds -- Biotechnology Value Fund (BVF), Orbimed Advisors and Black Horse Capital -- added significant new Oncothyreon positions in the second quarter. Each firm owned well over 1 million shares of the company as of June 30. Antipodean Advisors bought 1.6 million shares during the quarter to bring its total holding to 2.3 million shares.

Selling hedge funds included RA Capital, which liquidated its 236,000-share position in Oncothyreon during the second quarter. Straus Capital Management and Highland Capital Management also were sellers.
2 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $1.82 -4.50%
DSCI $3.18 -2.20%
IDIX $24.50 0.20%
KERX $5.21 -7.60%
ONTY $1.18 -2.90%


Chart of I:DJI
DOW 17,659.62 -91.29 -0.51%
S&P 500 2,050.62 -12.75 -0.62%
NASDAQ 4,726.1570 -37.0670 -0.78%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs